The classic website will no longer be available as of June 25, 2024. Please use the modernized ClinicalTrials.gov.
Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

HKI-272 for HER2-Positive Breast Cancer and Brain Metastases

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT01494662
Recruitment Status : Active, not recruiting
First Posted : December 19, 2011
Last Update Posted : October 23, 2023
Sponsor:
Collaborators:
Translational Breast Cancer Research Consortium
Puma Biotechnology, Inc.
Information provided by (Responsible Party):
Rachel Freedman, MD, MPH, Dana-Farber Cancer Institute

Results Submitted - Not Posted on ClinicalTrials.gov
Results information has been submitted to ClinicalTrials.gov by the sponsor or investigator, but is not yet publicly available (or "posted") on ClinicalTrials.gov. The submitted information may not be available if it is pending Quality Control (QC) Review by the National Library of Medicine (NLM) or if issues identified during QC review are being addressed or corrected by the sponsor or investigator. NLM's limited QC review assesses for apparent errors, deficiencies, or inconsistencies. NLM staff do not verify the scientific validity or relevance of the submitted information.
Recruitment Status : Active, not recruiting
Actual Primary Completion Date : February 1, 2023
Estimated Study Completion Date : December 2023
Submission Cycle Results Submitted to ClinicalTrials.gov Results Returned after Quality Control Review
1 March 21, 2024
April 17, 2024
2 April 25, 2024
 
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):